We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
Poster

Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies

Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
Poster

Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies

Immunotherapy aims to boost a patient’s own immune system to fight disease. In recent years, a variety of immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of cancer and autoimmune disease.

Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.

Specifically, we developed two bioluminescent reporter-based bioassays to measure T cell activation via CD3 (NFAT-RE) or CD3 + CD28 (IL-2 promoter). These
Advertisement